New Results
Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance
Clara Alcon, Albert Manzano-Muñoz, Estela Prada, Jaume Mora, Aroa Soriano, Gabriela Guillén, Josep Roma, Josep Samitier, Alberto Villanueva, View ORCID ProfileJoan Montero
doi: https://doi.org/10.1101/2020.01.24.918532
Clara Alcon
1Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), 08028 Barcelona, Spain
Albert Manzano-Muñoz
1Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), 08028 Barcelona, Spain
Estela Prada
2Developmental Tumor Biology Laboratory, Institut de Recerca Sant Joan de Déu, 08950 Esplugues de Llobregat, Spain
3Department of Haematology and Oncology, Hospital Sant Joan de Déu Barcelona, 08950 Esplugues de Llobregat, Spain
Jaume Mora
2Developmental Tumor Biology Laboratory, Institut de Recerca Sant Joan de Déu, 08950 Esplugues de Llobregat, Spain
3Department of Haematology and Oncology, Hospital Sant Joan de Déu Barcelona, 08950 Esplugues de Llobregat, Spain
Aroa Soriano
4Group of Translational Research in Child and Adolescent Cancer, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain
Gabriela Guillén
4Group of Translational Research in Child and Adolescent Cancer, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain
5Department of Surgery, Universitat Autònoma de Barcelona (UAB), 08193. Barcelona, Spain
Josep Roma
4Group of Translational Research in Child and Adolescent Cancer, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain
Josep Samitier
1Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), 08028 Barcelona, Spain
6Department of Electronics and Biomedical Engineering, University of Barcelona (UB), 08028 Barcelona, Spain
7Networking Biomedical Research Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 28029 Madrid, Spain
Alberto Villanueva
8Program against Cancer Therapeutic Resistance (ProCURE), IDIBELL, Catalan Institute of Oncology, 08907 l’Hospitalet del Llobregat, Barcelona, Spain
9Xenopat S.L., Business Bioincubator, Bellvitge Health Science Campus, 08907 l’Hospitalet de Llobregat, Barcelona, Spain
Joan Montero
1Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), 08028 Barcelona, Spain
Posted January 25, 2020.
Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance
Clara Alcon, Albert Manzano-Muñoz, Estela Prada, Jaume Mora, Aroa Soriano, Gabriela Guillén, Josep Roma, Josep Samitier, Alberto Villanueva, Joan Montero
bioRxiv 2020.01.24.918532; doi: https://doi.org/10.1101/2020.01.24.918532
Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance
Clara Alcon, Albert Manzano-Muñoz, Estela Prada, Jaume Mora, Aroa Soriano, Gabriela Guillén, Josep Roma, Josep Samitier, Alberto Villanueva, Joan Montero
bioRxiv 2020.01.24.918532; doi: https://doi.org/10.1101/2020.01.24.918532
Subject Area
Subject Areas
- Biochemistry (11718)
- Bioengineering (8724)
- Bioinformatics (29132)
- Biophysics (14936)
- Cancer Biology (12051)
- Cell Biology (17360)
- Clinical Trials (138)
- Developmental Biology (9406)
- Ecology (14146)
- Epidemiology (2067)
- Evolutionary Biology (18269)
- Genetics (12223)
- Genomics (16768)
- Immunology (11844)
- Microbiology (28016)
- Molecular Biology (11560)
- Neuroscience (60822)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3231)
- Physiology (4940)
- Plant Biology (10401)
- Synthetic Biology (2878)
- Systems Biology (7333)
- Zoology (1642)